ALKEMNSEAlkem Laboratories LimitedLowNeutral
Announced Fri, 20 Mar · 21:18 IST

Alkem Laboratories Limited has informed the Exchange regarding a press release dated March 20, 2026, titled "Intimation regarding receipt of EU GMP Certificate for the Company s manufacturing facility located at Daman, India".

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.4%1-day move
₹5280.00
prior close
₹5260.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.1-1.5-1.5-1.8+0.4+2.9-0.2+0.4-0.6-0.6+5.1+4.9+2.3+2.3
Up moveDown movePending
AI summary

Alkem Laboratories has received a Certificate of GMP Compliance for its manufacturing facility located in Daman, India, from the Malta Medicines Authority. The certification follows a GMP inspection conducted on 9th December 2025 at the facility, which was previously intimated to the exchanges. The certificate is valid for a period of three years from the date of inspection. Malta Medicines Authority is an EU regulatory body, so this certification enables Alkem to manufacture and supply pharmaceutical products to European Union markets from this Daman plant.

Likely market impact

Positive for shareholders — EU GMP clearance opens the door for Alkem to tap regulated European markets, potentially boosting export revenues and long-term business growth from the Daman facility.